Mrs Sharon Hodgson

Mrs Sharon Hodgson

Labour — Washington and Gateshead South

Speaking in the House of Commons on 17 November 2026

Debate

Medicines and Healthcare Products Regulatory Agency

Contribution

It is a pleasure to serve under your chairmanship, Sir John. I thank the co-chairs of the all-party parliamentary group for calling this important debate and for bringing to light an issue that is vital to every aspect of patient safety. From mesh to Poly Implant Prothèse breast implants, and from thalidomide to sodium valproate, the MHRA has shown time and again that it needs a complete overhaul of its approval systems, which seem to leave transparency and patient safety at the door. We promised thalidomide victims back in 1973 that nothing like that scandal would every happen again, yet we have seen scandal after sandal since. After the thalidomide scandal came the sodium valproate scandal. The drug was approved for nationwide prescription just a year after thalidomide was banned. At the same time, the forerunner to the MHRA decided it was best not to mention the adverse effects of sodium valproate on animal foetuses as it would give way to “fruitless anxiety”. That “fruitless anxiety” meant the campaigners for foetal valproate syndrome, who we all know well—Janet Williams and Emma Murphy—were dismissed by the MHRA. The MHRA is at the heart of the epidemic of medical scandals and, quite frankly, like the right hon. Member for Tatton (Esther McVey), I have had enough. The Government urgently need to launch an inquiry to put an end to the chain of scandals before there is more harm on the MHRA’s hands. The MHRA’s priority needs to be no longer just risk minimisation, but risk prevention. The pharmaceutical company that produced sodium valproate issued warnings about the teratogenic nature of the product. The forerunner to the MHRA shamefully decided to ignore those warnings and not disclose them to patients. As another example of harm—of which there are so many—as recently as 2017, the director of medical devices at the MHRA explained that using mesh during surgery was perfectly safe based on its evidence. Weeks later, the Food and Drug Administration in the USA banned the use of vaginal prolapse mesh due to the harm it was causing women. The wonderful Baroness Cumberlege, who so many of us worked with on her excellent report, paused sling mesh surgery for incontinence just a year later.

More from Mrs Sharon Hodgson

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

For Mrs Sharon Hodgson's full parliamentary record including voting history, expenses and all other contributions, see the Mrs Sharon Hodgson report card.